Novo Nordisk reports effective trial data on its obesity drug

Novo Nordisk reported its new data from the phase 3a SCALE Obesity and Prediabetes trial


(Photo Courtesy:

The results were presented at ObesityWeek 2014, the 2nd Annual Congress of The American Society for Metabolic and Bariatric Surgery and The Obesity Society.

According to the company, 92 percent (9 out of 10) of trial participants lost weight with liraglutide 3 mg treatment, in combination with diet and exercise, compared with 65% on placebo treatment.

People who completed the trial (56 weeks) demonstrated significantly greater weight loss of 9.2 percent compared with a 3.5 percent reduction in the placebo group (estimated difference [ED] 5.7 percent, p < 0.0001).

In addition, weight loss with liraglutide 3 mg was similar across a range of baseline body mass index (BMI) subgroups in people with obesity, from overweight to Class III obesity, at 56 weeks (p=0.054, %; p=0.54, kg) and independent of prediabetes status at screening (-8.0% with vs -7.9% without, p=0.59).

A larger proportion of people treated with liraglutide 3 mg completed the trial compared with those on placebo (72 percent vs. 64 percent).


Previous 1 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email